StemCell Therapy

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.

Reaching the revenues of over US$ 6 Bn at the end of 2019, the globalneuropathic pain management marketis projected for a healthy CAGR during the forecast period (2019 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4149

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4149

Key Takeaways Neuropathic Pain Management Market Study

Increasing prevalence of diabetic neuropathy and availability of approved neuropathy pain medications have significantly added to the opportunities for market growth, thereby fostering the rate of adoption of neuropathic pain management drugs.

Increasing R&D Spending by Pharmaceuticals Companies Shaping Future

One of the key factors observed to impact the neuropathic pain management market growth is the development of new drugs for treatment of neuropathic and chronic pains. Companies are focusing on clinical trials to develop drugs for efficient treatment of neuropathic pain. For instance, Eli Lilly and Company developed Duloxetine (LY248686) for Diabetic Peripheral Neuropathic Pain (DPNP) that is under phase 4 clinical trial.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4149

At the same time, companies are focused on expanding therapeutic applications of drugs such as opioids and steroids for neuropathic pain management without causing any serious side effects to patients. Currently, more than 100 clinical trials are been carried out for pain management. Among those clinical trials, nearly half of the clinical trials are for various indications of neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia.

What Does the Report Cover?

The neuropathic pain management market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the neuropathic pain management market during 2014 2018 and presents demand projections during 2019 2029 on the basis of drug class (tricyclic anti-depressants, anticonvulsants, SNRIs, capsaicin cream, local anesthesia, opioids, steroids, and others), indication (diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies) across prominent regions (North America, Latin America, Europe, Asia Pacific and MEA).

What the report encloses for the readers:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Liquid Chromatographymass Spectroscopy MarketLiquid Chromatography-Mass Spectroscopy Segmented By Triple Quadrupole, Time of Flight, Quadrupole Technology in Clinical Testing, Environmental Testing, Forensic Testing.For More Information

Biopharmaceutical MarketBiopharmaceuticals Market Segmented By Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor, Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins Type for Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

View post:
Neuropathic Pain Market to Witness CAGR 5.6% Growth in Revenue During the Period 2024 - WaterCloud News

THE WOODLANDS, TX - A number of Houstons aging residents are turning to non-invasive regenerative therapies to get relief from chronic pain associated with degenerative conditions like osteoarthritis, neuropathy, back and joint pain.

Doctors Jeffery Pruski, D.C., and Edward Nash, M.D., are pain management and regenerative medicine specialists at 3R Regenerative Repair & Relief (3R), located just outside of Houston in The Woodlands, Texas. Over the past three years, the doctors have seen a steady rise in patients over the age of 55 looking for alternatives to knee replacements, back surgeries, and opioid pain medications to relieve chronic pain.

As we age, the body loses its natural ability to heal itself, said Dr. Pruski. Unlike traditional pain management, which typically treats the symptoms of the pain with surgery or medications, regenerative therapies treat the root cause of the pain. It creates a healing environment inside the joint, or area of degeneration, that uses the bodys own healing capacity to regenerate healthy cells and restore normal function to damaged areas.

Older adults are more likely to experience chronic pain conditions like osteoarthritis, cancer, neuropathies and osteoporotic-related fractures.

Dr. Pruski believes more seniors are choosing regenerative therapies over traditional treatments out of concerns with taking opioid medications and because, compared to surgery, there is no trauma to the body, no anesthesia, no cutting of the skin or foreign implants; all of which pose additional health risks to one of our most vulnerable populations.

Roughly 60% of the patients treated at 3R are 55 or older. Doctors Pruski and Nash use a combination of non-invasive modalities approved by the FDA, including physical therapy, chiropractic care, regenerative medicine and biological therapy to help aging patients relieve pain and inflammation, speed recovery of injured or damaged areas, and improve their quality of life.

Dr. Pruski said while treatments vary for each individual patient, the doctors at 3R are seeing very successful outcomes treating aging patients suffering from chronic pain with the use of advanced technologies and interventions such as Regenerative Injection Therapies, Pulsed Electromagnetic Field (PEMF) therapies and Hako-Med therapy, which stimulates the nerves to provide muscle re-education and pain relief for a variety of degenerative joint conditions and nerve problems, along with muscle work, massage therapy and home exercise.

Our entire focus is preventative and regenerative care so that patients of all ages and all activity levels can maintain a healthy, pain-free life, said Dr. Pruski. We see everyone from professional and retired pro athletes, to everyday people who just want to be able to pick up their grandkids or make themselves a cup of coffee without pain. Todays technology allows us to accomplish healing and pain management goals for all of our patients in the most pain-free, non-invasive way possible. Most treatments last less than 30 minutes, require nothing more than a Band-Aid, with no recovery or down time, and you can drive yourself home.

Most insurance companies cover the majority of treatments at 3R Regenerative Repair & Relief, however coverage for biologic injection procedures may vary from policy to policy.

For more information on services and telemedicine consultations at 3R please visit https://www.3RRegenerativeMedicine.com.

See the original post:
Regenerative Therapies Helping Houston Seniors Find Non-Surgical Relief from Chronic Pain, Arthritis at Woodlands Clinic - Woodlands Online

(WZAW) -- Scientists around the world are racing to understand COVID-19 and the novel coronavirus that causes the disease. Among the questions theyre asking is why do most people who are infected show mild to moderate symptoms, or possibly no symptoms at all, whereas others develop a severe form of the disease.

To help gather more insights, DNA company 23andMe has launched a research study to help determine whether genetics may play a role. 23andMes unique research model, with millions of customers consenting to participate, offers their scientists a powerful tool for potential insight into the role genetics may play in explaining differences in the severity of the novel coronavirus.

With more than 400,000 existing 23andMe customers already enrolled to participate, including several thousand whove confirmed they had the virus, 23andMe is opened enrollment to people who have been hospitalized with the disease but are not currently customers. Opening up the research to individuals with more severe symptoms will increase their ability to learn how genes may play a role in the severity of this disease.

Joyce Tung, vice president of research at 23andMe joined NewsChannel 7 at 4 on Tuesday to talk about how the research is helping to understand the role genetics plays in the severity of COVID-19 symptoms.

Based on our past studies on infectious diseases, for some of those we saw that genes for example that are part of the immune system influence the susceptibility too in severity of those diseases, Tung explained.

Tung said researchers hope genetics can give us insights into the biological pathways in humans that influence the severity of the disease.

And perhaps with this information, we can develop different treatments, she added.

Continued here:
Researchers look at the role genetics play in the severity of coronavirus symptoms - WSAW

Cancer metastasis is a major cause of death which has attracted intense scientific research over the years. Metastasis is the process where cancer propagates to other tissues from where it started initially. It has long been thought that the genetic mutations which occur in the cells that cause cancer in them can also provide these cells with the ability to pervade other tissues further. But a question remainsdoes the inherited genetic make up of a person have a role in metastasis?

Before proceeding further, let us quickly recapitulate some facts. In most cancers, the genetic mutation occurs in somatic cells. This means that these cancer-causing genetic mutations are not inherited. For a genetic mutation to be called inherited, the mutations must have occurred in the germ cells, that is the cells involved in reproduction. Precisely, the egg cells and the semen.

The somatic mutations occur in a lifetime mostly due to external factors, like life style habits or environmental factors.

Apart from the somatic mutations, what the inherited mutations do in cancer metastasis has been a profound question in cancer research. Now, a Nature Medicinepublication has come out with some elaborated data which indicate the link between cancer metastasis and someones inherited genetics.

This study is based on melanoma, a type of cancer of the skin and finds that a single gene can alter the level of metastasis in this kind of cancer. The researchers also think that this gene and others can have similar effects in other cancer types.

The specific gene in question is the APOE gene, which is present in all types of cells of the body. The production of the gene, a particular protein, appears to have interference in a number of processes that cancer cells undertake to metastasise. The important processes are like forming blood vessels, penetrating deep into other healthy tissues as well as resisting attacks of bodys cancer targeting immune cells.

The APOE gene has three types, namely, ApoE2, ApoE3, ApoE4. An individual carries one type of the APOE gene among its varieties. It has been found that different melanoma patients have different degrees of progression of the cancer. The probable answer to it could be the presence of different APOE genes in different people.

In the latest study, experiments with mice show that those possessing the ApoE4 variety of the gene have the smallest tumour and also the least spread of melanoma. Also, it was found that ApoE4 is the most effective version of the gene that could provide enhanced immune response to tumour cells. In comparison with other types of the APOE gene, mice having the ApoE4 type have higher amount of T cells involved in fighting melanoma tumour along with reduced blood vessels. Benjamin Ostendorf, the first author of the study says, We think that a major impact of the variations in ApoE arises from differences in how they modulate the immune system's attack.

Recruiting genetic data from more than 300 melanoma patients also showed similar results as in the mice. Patients possessing the ApoE4 type could survive the longest and patients with ApoE2 type survived the least. While, the ApoE3 types ability to suppress tumour progression lies in between the other two.

The genetic inheritance and its link to cancer progression is hoped to better development of cancer therapeutics in future.

View post:
How Spread of Cancer Is Related to Genetics - NewsClick

People with a genetic mutation that increases the risk of dementia also have a greater chance of having severe Covid-19, researchers have revealed.

The study is the latest to suggest genetics may play a role in why some people are more vulnerable to the coronavirus than others, and could help explain why people with dementia have been hard hit: dementia is one of the most common underlying health conditions among those who have died from Covid-19 in England and Wales.

It is not just age: this is an example of a specific gene variant causing vulnerability in some people, said David Melzer, a professor of epidemiology and public health at Exeter University and a co-author of the study.

Writing in the Journal of Gerontology: Medical Sciences, Melzer and colleagues report how they analysed data from the UK Biobank, a research endeavour that has collected genetic and health data on 500,000 volunteers aged between 48 and 86.

The team focused on a gene called ApoE this gives rise to proteins involved in carrying fats around the body, and can exist in several forms. One such variant, called e4, is known to affect cholesterol levels and processes involved in inflammation, as well as increasing the risk of heart disease and dementia.

The researchers found 9,022 of almost 383,000 Biobank participants of European ancestry studied had two copies of the e4 variant, while more than 223,000 had two copies of a variant called e3. The former, the team add, have a risk of dementia up to 14-fold higher than the latter.

The team then looked at positive tests for Covid-19 between 16 March and 26 April when testing for the coronavirus was largely carried out in hospitals, suggesting the cases were severe.

The results reveal 37 people who tested positive for Covid-19 had two copies of the e4 variant of ApoE, while 401 had two copies of the e3 variant. After taking into account various factors, including age and sex, the team say people with two e4 variants had more than double the risk of severe Covid-19 than those with two e3 variants.

Melzer said the findings were not down to people with two e4 variants being more likely to be living in a care home settings that have been hard hit by Covid-19 since the association remained even when the team excluded participants with a diagnosis of dementia. None of the Covid-19 positive participants with two e4 variants of the ApoE gene had a dementia diagnosis.

It is pretty bulletproof whatever associated disease we remove, the association is still there. So it looks as if it is the gene variant that is doing it This association is not driven by people who actually have dementia, said Melzer.

The team say further work is needed to unpick the link.

Prof Tara Spires-Jones, an expert in neurodegeneration at the University of Edinburgh who was not involved in the study, said the large number of Biobank participants meant the association between the ApoE genetic variants and Covid-19 risk was robust, but stressed the study did not prove the former caused the latter. Nevertheless, she said, the study was important.

It is possible that the role of ApoE in the immune system is important in the disease and future research may be able to harness this to develop effective treatments, she said.

Fiona Carragher, a director of research and influencing at Alzheimers Society, said people with dementia and their families were desperately worried, adding the government must take urgent action to protect people with dementia. But, she said, more research was needed to delve into the possible link between the e4 variant of ApoE and severe Covid-19.

Other factors may contribute, so it is difficult to draw firm conclusions at this stage. But clearly much more in-depth research is urgently needed to fully understand why people with dementia seem to be at a higher risk and to what extent factors like ethnicity and genetics might play a role, she said.

But Prof David Curtis, honorary professor at the UCL Genetics Institute, urged caution. He noted that among the studys limitations, diagnoses of dementia in recent years are unlikely to be captured, meaning that the link between the e4 variant and severe Covid-19 may still be driven by more people with two e4 variants having dementia than those with two e3 variants.

Im afraid this study does not really convince me that the ApoE e4 allele [gene variant] is really an independent risk factor for severe Covid-19 infection, he said. I would want to see this tested in a sample where dementia could be more confidently excluded, perhaps a younger cohort. I am sure additional data will soon emerge to illuminate this issue.

Go here to read the rest:
Research reveals gene role in both dementia and severe Covid-19 - The Guardian

Saeed Khoshnood,1,2 Mohammad Savari,1,2 Effat Abbasi Montazeri,1,2 Ahmad Farajzadeh Sheikh1,2

1Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 2Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Correspondence: Ahmad Farajzadeh SheikhInfectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khuzestan 61357-15794, IranTel +98 9161133491Fax +98 61 3333 2036Email farajzadehah@gmail.com

Introduction: Acinetobacter baumannii is an opportunistic pathogen responsible for nosocomial infections. The emergence of colistin-resistant A. baumannii is a significant threat to public health. The aim of this study was to investigate the molecular characterization and genotyping of clinical A. baumannii isolates in Southwestern Iran.Methods: A total of 70 A. baumannii isolates were collected from patients admitted to Imam Khomeini Hospital in Ahvaz, Southwestern Iran. Minimum inhibitory concentration test was conducted by using Vitek 2 system. The presence of biofilm-forming genes and colistin resistance-related genes were evaluated by PCR. The isolates were also examined for their biofilm formation ability and the expression of pmrA and pmrB genes. Finally, multilocus sequence typing (MLST) and PCR-based sequence group were used to determine the genetic relationships of the isolates.Results: Overall, 61 (87.1%) and 9 (12.8%) isolates were multidrug-resistant (MDR) and extensively drug-resistant (XDR), respectively. Colistin and tigecycline with 2 (2.8%) and 32 (45.7%) resistance rates had the highest effect. Among all the isolates, 55 (78.5%), 7 (10%), and 3 (4.3%) were strong, moderate, and weak biofilm producers, respectively. The frequency rates of biofilm-related genes were 64 (91.4%), 70 (100%), 56 (80%), and 22 (31.42%) for bap, ompA, csuE, and blaPER1, respectively. Overexpression of pmrA and pmrB genes was observed in two colistin-resistance isolates, but the expression of these genes did not change in colistin-sensitive isolates. Additionally, 37 (52.8%) and 8 (11.4%) isolates belonged to groups 1 (ICII) and 2 (IC I), respectively. MLST analysis revealed a total of nine different sequence types that six isolates belonged to clonal complex 92 (corresponding to ST801, ST118, ST138, ST 421, and ST735). Other isolates were belonging to ST133 and ST216, and two colistin-resistant (Ab4 and Ab41) isolates were belonging to ST387 and ST1812.Conclusion: The present study revealed the presence of MDR and XDR A. baumannii isolates harboring biofilm genes and emergence of colistin-resistant isolates in Southwestern Iran. These isolates had high diversity, which was affirmed by typing techniques. The control measures and regular surveillance are urgently needed to preclude the spread of these isolates.

Keywords: Acinetobacter baumannii, drug resistance, colistin, MLST, clonal complex

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View post:
Survey on Genetic Diversity, Biofilm Formation, and Detection of Colis | IDR - Dove Medical Press

A Snohomish County man who was the countrys first confirmed COVID-19 patient was probably not the source of the coronavirus outbreak in Washington state, according to a new genetic analysis by an international group of scientists.

The finding upends one of the most compelling scientific narratives of the pandemics arrival in the United States, but it also showcases the power of quick public-health action, said Michael Worobey, lead author of the report and head of the University of Arizonas Department of Ecology and Evolutionary Biology.

As researchers learn more about the pandemics roots, its becoming clear that the virus entered the United States via multiple paths and at multiple times. But Washington still seems to be the place where it first took hold in this country and flared into a community outbreak, said co-author Joel Wertheim, a molecular epidemiologist at the University of California, San Diego.

The Snohomish County man, sometimes erroneously referred to as patient zero, started feeling sick after he returned Jan. 15 from a visit to Wuhan, China the pandemics birthplace. He was confirmed positive Jan. 20. Public-health officials tested and isolated everyone they could identify who came into contact with him, and found no other infections.

So it was baffling when a second case emerged Feb. 28 and genetic analysis showed it was similar to the first, differing by only two mutations. Trevor Bedford, a computational biologist at the Fred Hutchinson Cancer Research Center, and his colleagues, concluded that the two cases were linked with the Snohomish County man as the original source. They also estimated the virus had been spreading silently for six weeks.

But the new analysis, which was posted Monday on the preprint site bioRxiv and has not been peer-reviewed, says its more likely that quick action by public-health officials succeeded in stamping out any spread from the first infection, turning it into a dead end. The outbreak that eventually flared in late February and early March was probably the result of a separate introduction from China around Feb. 13, either directly or by way of British Columbia, Worobey and his colleagues argue.

To reach that conclusion, the team examined many more viral genomes than had been available earlier in the outbreak and found none in Washington that exactly matched the earliest known infection. They also found none of the expected missing link genomes, intermediate between the first case and subsequent infections.

They then used computer simulations to, as Worobey put it, rerun the tape of evolution over and over again. Thousands of times, in fact, to see how the viral genomes would be expected to change and evolve. Again, they found no indication that the viral strain carried by the Snohomish County man was the source of the states spreading outbreak.

To understand how a closely related strain might have been introduced separately, the team examined travel patterns and found that the Feb. 2 ban on air travel from China was actually quite leaky, with an estimated 40,000 U.S. residents returning to the United States from China via airports including Seattle-Tacoma International Airport.

The remaining influx likely provided ample opportunity for a second introduction to Washington State, the report says. It is also possible that the virus entered via nearby Vancouver, British Columbia, which is closely linked to both China and Washington state.

But Dr. Jared Roach, a senior research scientist at the Institute for Systems Biology in Seattle, said the new analysis is not likely to be the final word. Among other things, the model the researchers used for their simulations didnt appear to account for super-spreader events, like a choir practice where many people were infected, which could affect the virus evolutionary path, he said. Nor did it account for other possible variations in the way the virus spread, with some lineages fizzling out and others catching fire.

They are far too confident their answer is the only answer, Roach said. I think there are other explanations they didnt consider.

In a series of 18 tweets Monday, Bedford said he now agrees a second introduction was probably responsible for Washingtons outbreak. However, hes still convinced that second seed was planted fairly early, sometime between Jan. 18 and Feb. 9.

The exact timing is difficult to determine, Worobey said. But the implications are important.

If the virus had a six-week head start, spreading unseen and, thus, untouchable by public-health measures, then it was essentially hopeless theres not much anyone could have done to prevent the eventual flare-up.

But if, as the new analysis suggests, the virus didnt take hold until mid-February, then control might have been possible if the country hadnt fumbled the rollout of testing and tracing capacity.

The timing suggests strongly that those weeks that were lost were pretty consequential weeks, and that we did have more of a chance (of stopping it) than we realized, Worobey said.

The paper also criticized the U.S. Food & Drug Administration for halting the Seattle Flu Study, which could have provided valuable insights into the early spread of the virus. The project, funded by Bill Gates, had been collecting nasal swabs from volunteers across King County to study the spread of respiratory disease. Their samples represented a potential wealth of information, but researchers were initially barred from accessing that information because the project lacked specific approval to test the samples for the coronavirus.

The timeline of the pandemics spread is being revealed in bits and pieces, and a full picture probably wont emerge for quite some time. At least two Washington residents who were sick in December later tested positive for antibodies to the new coronavirus, though its not clear when their infections occurred. The first recorded death in the United States occurred in Snohomish County on Feb. 26, but posthumous analyses in California confirmed two earlier fatalities, the first on Feb. 6.

Read more:
New analysis may rewrite the history of Washington states coronavirus outbreak - Seattle Times

Dementia is one of the most common underlying health conditions in people who have died from the novel coronavirus in England and Walesnow British researchers say they might know why. A study has found that people with a specific genetic mutation known to increase the risk of dementia also have a much greater chance of having severe COVID-19, according to The Guardian. Its the latest study to suggest genetics may play a role in why some people are hit harder by the coronavirus than others, and could help explain why people with dementia appear to be particularly vulnerable. It is not just age: This is an example of a specific gene variant causing vulnerability in some people, said study co-author David Melzer, a professor of epidemiology and public health at Exeter University. The team found that having the gene that raises the risk of dementia could make people twice as likely to suffer badly from the virus.

Read the original:
Genetic Mutation Appears to Link COVID-19 to Dementia, Study Finds - The Daily Beast

Israeli scientists at the Israel Institute for Biological Research (IIBR) have found that a combination of two existing antiviral drugs for Gauchers disease appears to inhibit the growth of SARS CoV-2, the virus that leads to COVID-19 and may work against other virus infections, including a common flu strain.

The IIBR is a governmental research center specializing in biology, chemistry and environmental sciences that falls under the jurisdiction of the Prime Ministers Office. During the pandemic, announcements have been issued by the Defense Ministry.

According to a press announcement on Tuesday, scientists at the secretive bio-defense lab tested an analog of the FDA-approved drug Cerdelga, and an analog of a second drug, Venglustat, currently in advanced trials. They found that, in combination, the drugs led to a significant reduction in the replication capacity of the coronavirus and to the destruction of the infected cells.

The two drugs are used to treat Gaucher disease, an inherited genetic condition most common in people of Ashkenazi Jewish descent that leads to the buildup of fatty substances in certain organs, particularly the spleen and liver, and can affect their function. The disease can also lead to skeletal abnormalities and blood disorders, In rare cases, Gauchers disease can also lead to brain inflammation, according to the Mayo Clinic. The disease is unrelated to COVID-19.

The Israeli researchers tested the drugs on mouse models using four different RNA viruses: Neuroinvasive Sindbis virus (SVNI), an infection transmitted via mosquitos that can lead to years of debilitating musculoskeletal symptoms; West Nile virus (WNV), also a mosquito-borne disease that can cause neurological disease and is potentially fatal; Influenza A virus, a strain of the flu; and SARS-CoV-2.

The researchers found that the two drugs were effective in all four cases. They work by inhibiting glucosylceramide synthase *GCS), an enzyme involved in the production of glucocerebroside, a lipid that accumulates in the tissues of patients affected with Gaucher disease. In the lab setting, they inhibited the replication of the viruses, and in the case of mice infected with SVNI, increased their survival rate.

In the case of COVID-19, the drugs have an antiviral effect on the SARS-CoV-2 clinical isolate in vitro, with a single dose able to significantly inhibit viral replication within 2448 h.

The two drugs are currently being tested for their effectiveness in treating animals infected with the coronavirus.

The study, published in bioRxiv, has not yet been peer-reviewed. The authors are all from the IIBRs Department of Infectious Diseases

The data suggests that GCS inhibitors can potentially serve as a broad-spectrum antiviral therapy and should be further examined in preclinical and clinical trial, the scientists wrote, adding that repurposing approved drugs can lead to significantly reduced timelines and required investment in making treatment available.

Treatment of a new disease such as COVID-19 using an existing, approved drug may serve as an effective short-term solution considering that one of the major challenges in addressing such a pandemic is the length of time it takes for both the research and approval phases of new drugs, the Defense Ministry wrote in the announcement.

The lab has been conducting various research into COVID-19 for several months, including studies on possible treatment and a vaccine. Israeli Prime Minister Benjamin Netanyahu tapped the institute in early February to begin development on inoculation. In early April, the center reported significant progressand trials on animals.

The institute has also been involved in plasma collection from Israelis who have recovered from COVID-19 to research antibodies, proteins made by the immune system that can attack the virus.

Earlier this month, the IIBR said it completed a groundbreaking scientific development toward a potential treatment based on an antibody that neutralizes SARS-CoV2. The development had three key parameters, according to the IIBR: first, the antibody is monoclonal (lab-made identical immune cells that are all clones of a unique parent cell), and contains a low proportion of harmful proteins; second, the institute has demonstrated the ability of the antibody to neutralize the coronavirus; and third, the antibody was specifically tested on SARS CoV-2.

The Ness Ziona-based institute said it is now pursuing a patent for its development after which it will approach international manufacturers.

A number of Israeli scientific teams and over 100 groups worldwide are currently working to develop a vaccine or a treatment for COVID-19.

At least 10 candidate vaccines are in clinical evaluation, including those of Massachusetts-based company Moderna which was the first to develop an experimental vaccine that went into trial quickly, and California-based biotech firm Gilead Sciences, which is evaluating the safety and efficacy of its novel antiviral drug Remdesivir, developed originally for Ebola, in adults diagnosed with COVID-19.

Last month, Israeli scientists at theMigal Galilee Research Institute formed a new company, MigVax, to further adapt a vaccine they developed for a deadly coronavirus affecting poultry for human use. The scientists had been working for four years to develop a vaccine for IBV (Infectious Bronchitis Virus) which affects the respiratory tract, gut, kidney and reproductive systems of domestic fowl.

Also in April, an Israeli scientist wasawarded a US patent for his innovative vaccine design for the corona family of viruses and indicated that he was on track to develop a vaccine for SARS CoV2.

Meanwhile, two Israeli bio-medical companies nabbed FDA approval for separate trials in the US with their respective solutions for COVID-19 as part of a compassionate use program, a treatment option that allows for the use of not-yet-authorized medicine for severely ill patients.

BothRedHill BioPharma, a publicly-traded specialty biopharmaceutical company, andPluristem Therapeutics, also a public company that specializes in placental cell therapy, were given the green light for their imminent separate studies with the investigational drug, opaganib, and the placental cell therapy PLX, respectively.

Continued here:
Israeli Lab: Drugs For Gaucher Disease May Work Against Coronavirus, Other Viral Infections | Health News - NoCamels - Israeli Innovation News

Market Expertz has very recently published a report on the Stem Cell Banking market, which delves deeper into a bunch of insightful as well as comprehensive information about the Stem Cell Banking industrys ecosystem. The research report on the Stem Cell Banking market covers both qualitative as well as quantitative details that focus entirely on the various parameters such as Stem Cell Banking market risk factors, challenges, industrial developments, new opportunities available in the Stem Cell Banking report. These factors are the ones that determine the functioning and trends in the forecasted period for the market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

Avail your copy of the sample of the report on the global Stem Cell Banking [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/122606

With the growing number of new players entering the Stem Cell Banking market, expansion in businesses is also improving. Then Stem Cell Banking report focuses on boosting a series of parameters such as revenue shares, optimizing cost structure, offering better services, Stem Cell Banking market demand or supply chain, development policies, which mainly maps to streamline business processes during the projected timeline.

The fundamental drivers, as well as restraints, are identified by the recent trends and historical milestones gathered by the Stem Cell Banking market. It also demonstrates the brief evaluation of the investments, Stem Cell Banking production, innovative technologies, and growth rate of the specific businesses.

Leading Stem Cell Banking manufacturers/companies operating at both regional and global levels:

Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico).

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketexpertz.com/checkout-form/122606

The creative advancements are investigated widely to understand the probable impact on the growth of the global Stem Cell Banking market.

The Stem Cell Banking market has been segmented into key segments such as product types, end-users, leading regions, and noteworthy players. The readers can assess detailed and strategical information about each segment. The Stem Cell Banking market report also includes a blend of statistics about sales, consumption rate, volume, value, gross margin, and more.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Stem Cell Banking sector and can help companies in deciphering the optimum business move to reach their desired business goals.

product landscape:

Placental Stem Cells (PSCS), Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells , (HESCS), Dental Pulp-Derived Stem Cells (DPSCS)

Application landscape:

Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation

End user landscape:

Personalized Banking Applications, Research, Clinical Application

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

To get in-depth insights into the global Stem Cell Banking market, reach out to us @ https://www.marketexpertz.com/customization-form/122606

Thus, with the rising adoption of the Stem Cell Banking market in the international sector, the industry for the global Stem Cell Banking market is expected to represent a predicted outlook during the forecast phase from 2020-2027. Additionally, the report on the Stem Cell Banking market delivers a systematic representation of the growth opportunities, Stem Cell Banking market dynamics, and the existing trends are anticipated to shape the growth of the Stem Cell Banking market across the globe.

Geographically, this report studies the top producers and consumers in these key regions:

North America

Europe

China

Japan

Southeast Asia

India

A conscious effort is made by the subject matter experts to analyze how some business owners succeed in maintaining a competitive edge while the others fail to do so makes the research interesting. A quick review of the realistic competitors makes the overall study a lot more interesting. Opportunities that are helping product owners size up their business further add value to the overall study.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/122606

The Stem Cell Banking Market Research/Analysis Report addresses the following questions:

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, etc. @ https://www.marketexpertz.com/industry-overview/2020-stem-cell-banking-global-market

To summarize, the global Stem Cell Banking market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

Read the original here:
Impact of Covid-19 on Stem Cell Banking Market 2020: Remarking Enormous Growth with Recent Trends | Cord Blood Registry (CBR) Systems (US), Cordlife...

Scientists in the Department of Biomedical Engineering at Texas A&M University are seeking to advance the field of 3D bioprinting functional tissues, by conducting research into the development of new biomaterials.

Dr. Akhilesh K. Gaharwar, an associate professor in the department, has created a highly 3D printable bioink, which can be used as a platform for generating anatomical-scale functional tissues. The new material developed by Gaharwars research group, known as Nanoengineered IonicCovalent Entanglement (NICE) bioink, has been designed to overcome the deficiencies of current bioinks in relation to structural stability. Commenting on the benefits of the NICE bioink, Gaharwar states: The next milestone in 3D bioprinting is the maturation of bioprinted constructs toward the generation of functional tissues.

Our study demonstrates that NICE bioink developed in our lab can be used to engineer 3D-functional bone tissues.

Bioprinting bone tissue

In their study, Gaharwars research group first outlined the emergence of 3D bioprinting as a technique for fabricating patient-specific, implantable constructs for regenerative medicine. Using hydrogels and combining them with cells and growth factors, these bioinks are 3D printed to create tissue-like structures intended to imitate the function of natural tissues.

One particularly useful application of the technology is in patient-specific bone grafting, a surgical procedure that replaces missing bone in order to repair bone fractures. As traditional treatments for managing bone defects and injuries are slow and expensive, Gaharwar states that developing replacement bone tissues with bioprinting could create exciting new treatments for patients. These can be used to treat defects and conditions such as arthritis, bone fractures, dental infections and craniofacial defects.

Recent advancements in the field have come from Rice University and the University of Maryland (UMD). Scientists at these institutions have outlined a new proof-of-concept for 3D printing artificial bone tissue to help repair damage related to arthritis and sporting accidents.

In late 2019 onboard the ISS, 3D Bioprinting Solutions, a Russian bio-technical research laboratory, 3D bioprinted bone tissue in zero gravity. Leveraging its Organ.Aut 3D bioprinter, the labs researchers hope to one day create real bone implants for astronaut transplantation on long interplanetary missions.

Nanoengineered bioinks for stronger bone structures

In the bioprinting process, cell-laden biomaterials flow through a nozzle in liquid form, however immediately solidify as soon as theyre deposited. It is necessary for bioinks to act as cell carriers and structural components, which requires them to be highly printable while providing a robust and cellfriendly microenvironment.

As outlined in the research paper, Gaharwars team explain that current bioinks in use lack the sufficient biocompatibility, printability, structural stability and tissuespecific functions needed for preclinical and clinical applications of bioprinting. The potential applications of bioprinting have been limited due to the lack of bioinks capable of meeting the demands of both 3D printing and tissue engineering. For example, ideal bioinks must be capable of extruding into stable 3D structures, while also protecting cells during and after printing, and providing an appropriate environment that can be remodeled into the target tissue. Unfortunately, conventional hydrogels are weak and poorly printable, explain the authors.

In response to this issue, Gaharwars research group has developed the NICE bioink formulation specifically for 3D bone bioprinting. NICE bioinks are a combination of two reinforcement techniques (nonreinforcement and ionic-covalent network). Used together, they provide an effective reinforcement that results in much stronger bone structures. Explaining the benefits of the material, the researchers write: The NICE bioinks allow precise control over printability, mechanical properties and degradation characteristics, enabling custom 3D fabrication of mechanically resilient, cellularized structures.

Once the bioprinting process is complete, the cell-laden NICE networks are crosslinked to form stronger scaffolds. Using this technique, Gaharwar and his team have been able to produce full-scale, cell-friendly reconstructions of human body parts, including ears, blood vessels, cartilage and bone segments.

In their tests, the researchers found that the enclosed cells began depositing new proteins containing a cartilage-like extracellular matrix that subsequently calcifies to create a mineralized bone over a three-month period. Five percent of these 3D bioprinted scaffolds consisted of calcium, which is similar to cancellous bone, the network of spongy tissue typically found in vertebral bones.

Gaharwars research group used a genomics technique called whole transcriptome sequencing (RNA-seq) to examine how these bioprinted structures were able to induce stem cell differentiation. RNA-seq works by capturing a snapshot of all genetic communication inside the cell at a given moment. The team worked with Dr. Irtisha Singh, assistant professor at the Texas A&M Health Science Center, who served as a co-investigator.

Using their bioink and research results, Gaharwars team plans to demonstrate in vivo functionality of the 3D bioprinted bone tissue.

The study, Nanoengineered Osteoinductive Bioink for 3D Bioprinting Bone Tissue is published in ACS Applied Materials & Interfaces. It is written by David Chimene, Logan Miller, Lauren M. Cross, Manish K. Jaiswal, Irtisha Singh, and Akhilesh K. Gaharwar.

The nominations for the 2020 3D Printing Industry Awards are now open. Who do you think should make the shortlists for this years show? Have your say now.

Subscribe to the 3D Printing Industry newsletter for the latest news in additive manufacturing. You can also stay connected by following us on Twitter and liking us on Facebook.

Looking for a career in additive manufacturing? Visit 3D Printing Jobs for a selection of roles in the industry.

Featured image shows Dr. Akhilesh Gaharwar. Photo via Texas A&M Engineering.

Here is the original post:
Researchers develop nanoengineered bioink to 3D print functional bone tissue - 3D Printing Industry

Doctors say that what you eat may help with some of the inflammation we see with arthritis

by: Len Rome

(WYTV) Millions of Americans suffer from arthritismand sometimes it really hurts.

The most common form is degenerative arthritis, also known as osteoarthritis, followed by rheumatoid arthritis.

Doctors say that what you eat may help with some of the inflammation we see with arthritis.

John Davis III, M.D. Rheumatology from The Mayo Clinic says avoiding foods such as potato chips and pizza could help ease your arthritis pain.

Some foods can increase inflammation levels and contribute to symptoms of arthritis, especially really fatty foods simple sugars or carbohydrates, lots of salt or salty food.

The symptoms may include swollen and achy joints, discomfort and pain.

While medication may help joint pain, exercise, maintaining a healthy weight and paying attention to the food you eat play important roles.

Add more fruits and vegetables, healthy fats such as olive oil and nuts, whole grains and fish.

These foods can help reduce inflammation and ease pain.

Originally posted here:
Len Romes Local Health: The impact of foods on arthritis - WYTV

Arthritis has name recognition, even among people who are not suffering from it. But despite that recognition, arthritis is not as well understood as one might think.

According to the Arthritis Foundation, arthritis is not a single disease, but rather an informal way of referring to joint pain or joint disease. In fact, the term arthritis is so wide-ranging that it actually refers to more than 100 types of conditions.

Despite that complexity, arthritis often produces four important warning signs, regardless of which type of arthritis a person may have.

1. Pain

The Arthritis Foundation notes that arthritis-related pain may be constant or intermittent. One common misconception about arthritis pain is that it only occurs during or shortly after a body is at rest. However, arthritis-related pain can occur while the body is at rest and is not always triggered by an activity that incorporates a part of the body affected by arthritis. In addition, pain from arthritis can be isolated to one area of the body or affect various parts of the body.

2. Swelling

Skin over the joints affected by arthritis may become red and swollen. This skin also may feel warm to the touch. The Arthritis Foundation advises anyone who experiences this swelling for three days or longer or more than three times per month to contact a physician.

3. Stiffness

This warning sign is, along with pain, the one that is most often associated with arthritis, even by people who dont suffer from the condition. Stiffness when waking up in the morning or after long periods of being sedentary, such as sitting at a desk during the workday or taking a long car ride, can be symptomatic of arthritis, especially if the stiffness lasts an hour or longer.

4. Difficulty moving a joint

The Arthritis Foundation notes that people should not experience difficulty moving, such as when getting out of bed. People who experience such difficulty may have arthritis.

People who recognize any of these warning signs should report them to their physicians immediately. Be as specific as possible when describing these symptoms, as specificity can help physicians design the most effective course of treatment.

Read more:
Common warning signs of arthritis | Health | willistonherald.com - Williston Daily Herald

Psoriatic arthritis is a type of arthritis that develops in some people who have psoriasis, which is a chronic autoimmune disease of the skin.

Psoriatic arthritis can be mild, or it can be severeor it can be somewhere in between. But its important to understand that its a progressive disease. Although there are some very effective treatments to help you manage your condition and slow the progression, it can cause irreparable harm to your joints if left untreated.

May is Psoriatic Arthritis Awareness Month and the perfect time to learn more about this often-debilitating disease. Check out the National Psoriasis Foundation website for a variety of podcasts, webinars and other online research materials.

To make things tricky, though, psoriatic arthritis can resemble another form of arthritis: rheumatoid arthritis. They can be hard to differentiate, in fact.

Related: Know the 5 Types of Psoriatic Arthritis

Are you ready for this? Its also possible to have psoriatic arthritis and another form of arthritis, including rheumatoid arthritis. Yes, you can even have both psoriatic arthritis and rheumatoid arthritis at the same time. Since both are progressive diseases, its important to get the right diagnosis and know what you have so you can start treatment.

The earlier the treatment, the earlier that we can stop the joint damage, says rheumatologist Robert Hylland, MD, assistant clinical professor at Michigan State University College of Osteopathic Medicine.

Not everyone with psoriasis develops psoriatic arthritis. According to the National Psoriasis Foundation, about eight million people in the United States have psoriasis. Research suggests that between 10 and 30 percent of people with psoriasis go on to develop psoriatic arthritis.

Usually, but not always, the psoriasis comes first, says Erin M. Bauer, MD, a rheumatologist who practices in the Seattle area.

That means youll probably notice some plaques or scaly patches of psoriasis somewhere on your skin, first. However, there are occasions when a person will develop arthritis without noticeable signs of psoriasis first. Its rare, but its possible.

Time your workout right. Exercising in the morning is associated with lower blood pressure, better sleep and greater weight loss, while afternoon or evening exercise appears to be better at improving aerobic performance and strength. Most important, though, is to exercise regularlyno matter what time you choose.

Usually, psoriatic arthritis will begin with some swelling in a joint like a finger or a toe, says Bauer. In fact, dactylitis, which describes a digit thats completely swollen like a sausage, is a common sign of psoriatic arthritis.

While it may start in the joints close to your fingernails or toenails, psoriatic arthritis can go on to affect other joints, too, including the knees and the elbows. A few people even develop inflammation and swelling in their spines, a condition known as psoriatic spondylitis.

Rheumatoid arthritis is also a chronic autoimmune disease. Youre more likely to develop rheumatoid arthritis if you have a family history of RA. People over age 40 and women are also more at risk.

Experts havent pinpointed the exact cause of rheumatoid arthritis yet, but we do know that your bodys antibodies attack the joints if you have this condition. Typically, it affects the smaller joints firstthe small joints in the hands, feet and wrists. It causes swelling, pain and stiffness in these joints.

So what makes it different from psoriatic arthritis? It can be tough to determine without bloodwork, as there can be some overlap with the joints that both kinds can affect, notes Bauer. For example, both can affect the hips and knees, Bauer says.

Related:How to Keep Your Joints Healthy

If your doctor suspects you have rheumatoid arthritis, you may need to undergo some blood tests to look for high levels of inflammation and for specific antibodies that are commonly found in the bloodstreams of people with RA. Among others, the doctors will be looking for evidence of an antibody called the Rheumatoid Factor (RF) antigen and perhaps also cyclic citrullinated peptide antibodies (CCP).

However, there are two things that might help you distinguish the two types of arthritis from each other. One is fairly obvious: the presence of psoriasis lesions. Thats a cue that youre probably dealing with psoriatic arthritis.

But the other factor is the location of the affected joints. While there is possible overlap, they can and do affect different joints. For example, psoriatic arthritis tends to affect the joints closer to your fingernails, the joints known as distal interphalangeal joints. RA tends to affect the other joints in the hands, which are called the proximal interphalangeal (PIP) and metacarpophalangeal (MCP) joints. It also tends to affect the wrists, and the metatarsophalangeal (MTP) joints, or the small joints in your feet.

RA also tends to affect the same joint on both sides of the body, while its more common for psoriatic arthritis to only affect joints on one side of the body.

Related:What Does Arthritis Feel Like?

Rheumatoid arthritis tends to be more symmetric, says Bauer. So wed expect to see it on both sides, whereas psoriatic arthritis is not symmetric. You could have just one knee and one elbow affected.

Now the good news: treatment has come a long way in recent years.

There are a number of good treatment paradigms for psoriatic arthritis, and the likelihood of severe deformity like there was in the past is close to zero with the new therapies we have, Hylland says.

There are also effective treatments for managing rheumatoid arthritis. And while its possible to have both psoriatic arthritis and rheumatoid arthritis at the same time, that wont necessarily complicate your treatment plan.

The initial treatments are the same for both, says Bauer, noting that tumor necrosis factor (TNF) inhibitors work well for both types of arthritis, especially for people who cant take methotrexate, which is another first-line treatment. (TNF inhibitors block the action of a immune system protein called TNF, which causes inflammation.)

Celebrity interviews, recipes and health tips delivered to yourinbox.

Another med that can be used to treat either RA or psoriatic arthritis is a Janus kinase inhibitor, or JAK inhibitor, like tofacitinib. This type of drug interrupt your immune systems urge to overproduce lots of inflammation-causing proteins called cytokines. They may work better for you than other kinds of drugs and they have the bonus of being available in pill form, rather than an injection or infusion.

With either condition, its crucial that you dont ignore the symptoms until they become very severe. Early diagnosis is critically important for slowing the progression of these diseases.

The earlier we catch it, the less we have to do to quiet itthe less medication we have to use it quite it, says Hylland.

Next,What Is Restorative Yoga and How Will It Help You

Go here to see the original:
Learn the Differences Between Rheumatoid and Psoriatic Arthritis - Parade

In a desperate attempt to avoid the coronavirus or to make existing infections worse, arthritic patients are looking for alternative treatments for their ailment. Some even consider bizarre ones, such as the industrial lubricant, WD-40, in place of ibuprofen.

Many now fear the effects of the over-the-counter drug after previous speculations by scientists that it could make coronavirus symptoms worse. Ibuprofen has long been the drug of choice of arthritis, which many rely on to be able to walk without going through excruciating pain.

Sid Dajani, a pharmacist in Hampshire and former treasurer of the Royal Pharmaceutical Society, said that mixed messages about ibuprofen have caused people to avoid the drug altogether. According to Daily Mail, some have resorted to alternatives that seem rather odd, such as snake oils, aloe vera, and even the industrial degreaser, WD-40.

He adds that despite the NHS' latest advisory stating the drug is safe to take, sales remain to be at around a third of their normal levels.

Read Also: COVID-19: Arthritis Drug Saves 72-year-old Critically Ill Patient with Grim Condition

Worries about the drug started on March 14, when Olivier Veran, the French health minister said ibuprofen could aggravate coronavirus infections.

His comments are thought to be partly planted by remarks coming from an infectious diseases doctor. He mentioned about four young COVID-19 patients with no underlying health conditions developing severe symptoms after taking ibuprofen. A letter that had been published in the journal Lancet Respiratory Medicine three days earlier might have also caused him to believe this.

On March 16, the authors released a clarification statement saying they had merely been proposing a 'suspicion'. The following day, however, the NHS advised people with COVID-19 symptoms to avoid taking ibuprofen and instead use paracetamol.

Advice shifted again in April after the Commission on Human Medicines concluded that there is insufficient evidence that ibuprofen makes people more likely to catch COVID-19 or worsen its symptoms.

It has been reported that some were even using WD-40 on their joints, thinking that it will ease stiff joints the same way it loosens stubborn locks. Others tried using aloe vera while some went searching online for other adventurous remedies such as snake oil lotions and potions.

Dajani described how upsetting it is to see patients in pain turn to unproven or dangerous remedies when ibuprofen could help them. He describes the event as a tragedy that should not be happening.

Dr. Taher Mahmud, a consultant rheumatologist from the London Osteoporosis Clinic, said that it was 'very sad and concerning' that patients are utilizing faulty home remedies such as WD-40.

Experts believe that there is a distinct concern when it comes to pre-print and early drafts of medical and scientific papers that have not been peer-reviewed. These kinds of studies are particularly being given undue weight during the pandemic, being an easy target for criticisms and early speculations.

Also Read: Claims Ibuprofen Worsen COVID-19 are Baseless, According to EU

Original post:
Arthritis Patients Resort to Using Industrial Lubricant Over Fears Ibuprofen Might Worsen Coronavirus - Science Times

Ampersand Health has won a grant from Innovate UK to develop digital therapy solutions for people with rheumatoid arthritis.

The company was selected from over 8600 applications to receive funding by the UK government to develop digital self-management solutions for shielding RA patients.

Companies are set to benefit from a 40 million investment to drive forward new technological advances, particularly as a response to the COVID-19 outbreak.

Ampersand Health uses behavioural and data science to personalise pathways and support better self-care for people with long term inflammatory conditions. Its apps are designed to improve patients mental health and quality of life by helping address their stress management, medicine adherence, sleep quality, relationships and more; with courses for food choices and flare management in development.

The companys intervention for Crohns and Colitis patients was selected by NHSX and DHSC to be part of Techforce 19. As part of the programme, Ampersand showed that people who took its courses for a week experienced improvements in disease related quality of life and reductions in anxiety and depression.

The Innovate UK funding will allow the company and its partners - including the National Rheumatoid Arthritis Society - to invest in and evidence similar new behavioural medicines for people living with inflammatory arthritis.

A version of the platform is available for free - for the NHS via G-Cloud 11 and for patients via the app store.

Continue reading here:
Innovate UK grant to help develop digital solutions for rheumatoid arthritis - Med-Tech Innovation

The Rheumatoid Arthritis Treatment market report is an in-depth analysis of this business space. The major trends that defines the Rheumatoid Arthritis Treatment market over the analysis timeframe are stated in the report, along with additional pointers such as industry policies and regional industry layout. Also, the report elaborates on the impact of existing market trends on investors.

Latest Growth Report on Rheumatoid Arthritis Treatment Market size | Industry Segment by Applications (Hospital,Retail Pharmacies andDrugstores), by Type (Non-Steroidal Anti-inflammatory Drugs (NSAIDs),Corticosteroids andDisease-modifying anti-rheumatic drugs (DMARDs), Regional Outlook, Market Demand, Latest Trends, Rheumatoid Arthritis Treatment Growth Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2027. Analyzes current market size and upcoming seven years growth of this industry.

Other information included in the Rheumatoid Arthritis Treatment market report is advantages and disadvantages of products offered by different industry players. The report enlists a summary of the competitive scenario as well as a granular assessment of downstream buyers and raw materials.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/195609

Revealing a gist of the competitive landscape of Rheumatoid Arthritis Treatment market:

An outlook of the Rheumatoid Arthritis Treatment market regional scope:

Additional takeaways from the Rheumatoid Arthritis Treatment market report:

Objectives of the Global Rheumatoid Arthritis Treatment Industry Research Report: Forecast to 2027:

Key Questions Answered in this Market Research Report:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/195609

See the rest here:
Rheumatoid Arthritis Treatment Market Summary, Trends, Sizing Analysis and Fore - News by aeresearch

Aimee Staveley has finally opened up on the heartache and courage that is hidden behind her stellar career.

The 30-year-old Leeds Rhinos forward has won just about every honour in the womens game in the past few years.

But the fact that Staveley is able to play, let along succeed at the top level, is astonishing.

She was diagnosed with psoriatic arthritis eight years ago and admits there are days the physical pain is excruciating.

The mental battles, of knowing its a crippling condition that she will always suffer with, have also taken her to some dark places.

But staggeringly Staveley believes the bad luck that fate has dealt her has helped turned her into the fierce competitor she is today.

She said: The things I have achieved in rugby are totally beyond my wildest dreams and it is amazing when I look back at what Ive done.

But I never take any of it for granted and never look too far in front or get my hopes up because I never know when Ill get an infection or a flare-up or something that will knock me back.

Staveley has decided to speak out to help other sufferers and this week completed a 100km running challenge to raise money for Versus Arthritis.

But she admits its taken her eight years to get to the point where she feels comfortable talking about it.

She said: I never wanted people to know because I didnt want to be treated any differently or to be excluded from things.

The fatigue massively affects me and is there constantly even when the pain isnt. When I have a flare up the pain is so excruciating that it feels like Ive been turned to stone.

But Ive never wanted to make excuses for myself or for others to make excuses for me.

Staveley - a treble winner with Bradford in 2017, plus Grand Final and two times Challenge Cup winner with Leeds - has previously only confided her secret with her coaches.

She said: I needed them to know if I wasnt very well or was having a flare-up and theyve all been understanding.

But by telling them it just made me try even harder to prove myself. I get very stubborn with it.

Staveley, who is furloughed from work in her career as an assistant manager for Specsavers, is also a qualified plasterer.

She said: When I went to college it was at the start of the recession so I thought Id get a trade because I knew Id then be able to work anywhere in the world.

Sign up for the brilliant new Daily Star Sport email newsletter!

From the latest transfer news to the agenda-setting stories, get it all in your email inbox.

Put your email in the box at the top of this article or you can follow instructions on this link here.

Staveley is so tough she even did this interview during a 10km run as part of her charity fund-raiser.

She said: Im a forward because of my size but I have always been very good at stamina.

I wanted to set myself something that is really hard to do so I feel proud and I thought the best charity to do it for would be the one that is close to me.

Go here to see the original:
Leeds' Aimee Staveley opens up on arthritis diagnosis that has been career inspiration - Daily Star

In this report, the COVID-19 Impact on Global Psoriatic Arthritis Therapeutics Drug market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026. COVID-19 Impact on Global Psoriatic Arthritis Therapeutics Drug market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-psoriatic-arthritis-therapeutics-drug-market-insights-forecast-to-2026

Psoriatic arthritis is a chronic autoimmune inflammatory disorder that causes inflammation, swelling, and stiffness at any joint of the body. Psoriatic arthritis is a progressive form of psoriasis, characterized by the itchy, scaly red patches on the skin.

Asia Pacific is anticipated to dominate the global market over the forecast period owing to its high demand in the region.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Psoriatic Arthritis Therapeutics Drug market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Psoriatic Arthritis Therapeutics Drug industry.

Based on our recent survey, we have several different scenarios about the Psoriatic Arthritis Therapeutics Drug YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Psoriatic Arthritis Therapeutics Drug will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Psoriatic Arthritis Therapeutics Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Psoriatic Arthritis Therapeutics Drug market in terms of both revenue and volume.

Players, stakeholders, and other participants in the global Psoriatic Arthritis Therapeutics Drug market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on sales (volume), revenue and forecast by each application segment in terms of sales and revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Sales and Pricing Analyses

Readers are provided with deeper sales analysis and pricing analysis for the global Psoriatic Arthritis Therapeutics Drug market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.

In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Psoriatic Arthritis Therapeutics Drug market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Psoriatic Arthritis Therapeutics Drug market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Psoriatic Arthritis Therapeutics Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Psoriatic Arthritis Therapeutics Drug market.

The following manufacturers are covered in this report:

AbbVie

Janssen Biotech

Novartis

Amgen

CELGENE CORPORATION

Pfizer

Eli Lilly

UCB

Biogen

Bristol-Myers Squibb

Psoriatic Arthritis Therapeutics Drug Breakdown Data by Type

NF Inhibitors

Interleukin Inhibitors

PDE4 Inhibitors

Others

Psoriatic Arthritis Therapeutics Drug Breakdown Data by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-psoriatic-arthritis-therapeutics-drug-market-insights-forecast-to-2026

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 911 Central Avenue #268Albany New York 12206Email: [emailprotected]Phone: 1-518-730-1569Web: https://www.crystalmarketreport.com

Originally posted here:
COVID-19 Impact on Global Psoriatic Arthritis Therapeutics Drug Market Insights, Forecast to 2026 - 3rd Watch News

SynAct Pharma AB ("SynAct") today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company's lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases.

The application was filed in continuation of a preliminary European patent application the company filed in May 2019. The application includes data from a disease model of inflammatory joint diseases, the K/BxN model in mice. This arthritis model is associated with the formation of immune complexes that drive the activation of immune cells, such as neutrophils and macrophages, and the release of a number of immune mediators including cytokines and chemokines. Hence, the model mimics active stages of RA, where AP1189 currently is tested in Phase II as add-on treatment to MTX. AP1189 has previously been tested in the model (see J Immunol. 194:3381-8, 2015), and in the new dataset filed with the patent application the compound, at a sub maximal dose was given in combination with MTX. The study groups of animals were treated with either vehicle (controls), MTX, the sub-maximal dose of AP1189, or a combination with AP1189 and MTX. Treatment was started when arthritis symptoms were present, and the treatment effects were evaluated on day 7. At this timepoint, 75% of the vehicle-treated animals had developed severe disease defined as a clinical score of more than 10. In both the MTX and the AP1189 groups, 50% of the animals had developed severe disease. In the group of animals treated with the combination of AP1189 and methotrexate, no animals developed severe arthritis suggesting synergistic effects of AP1189 and MTX in RA. Further, no signs of toxicity were found in the animal treated with the AP1189 and MTX combination. The patent application will be public within 6 months from filing.

Thomas Jonassen, CSO SynAct Pharma states:

"The purpose of the patent application is to add an additional level of IP protection to our AP1189 compound. As the data generated in the animal model of RA suggest synergistic effects of AP1189 and MTX when given in combination, we have filed the claims for combination treatment of the compounds as applied in our ongoing Phase 2 study in RA. In addition to giving a broader patent protection, if granted as filed, this patent will also extend the patent runway for such combination therapy."

For further information about SynAct Pharma AB, please contact:

Jeppe vlesen Thomas Jonassen

CEO, SynAct Pharma AB CSO, SynAct Pharma AB

Phone: +45 28 44 75 67 Phone: +45 40 15 66 69Mail: joo@synactpharma.com Mail: tj@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms.

About AP1189

SynAct Pharma's drug candidate AP1189 is a melanocortin receptor agonist on MC1 and MC3 receptors and is in clinical phase II development for the treatment of active Rheumatoid Arthritis (RA):

https://clinicaltrials.gov/ct2/show/NCT04004429?term=AP1189&draw=2

https://news.cision.com/synact/r/synact-pharma-files-patent-application-for-combination-of-ap1189-and-methotrexate-for-treatment-of-r,c3118819

https://mb.cision.com/Main/14427/3118819/1252860.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

See the original post:
SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases -...